Frank Witney
Frank Witney's purchase track record
Frank Witney has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/9/2024 | CERS | $38K | +14.1% | -7.8% | +14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Revvity Announces Earnings Call, Analysts Upgrade Rating. Revvity has announced that it will conduct an earnings call on November 3, 2026. Analysts have upgraded the stock’s rating, citing stronger fundamentals and a positive outlook. Today’s trading saw unusual volume and the price is near its support level of $110.97 with an RSI of 68.9, indicating a moderately overbought condition.
Transaction History
| LAB | ▲ Buy | Grant | 99,116 | $0 | 6/18/2026 | View on chart |
| CERS | ▲ Buy | Grant | 60,000 | $0 | 6/2/2026 | View on chart |
| RVTY | ▲ Buy | Grant | 1,015 | $0 | 5/7/2026 | View on chart |
| RVTY | ▲ Buy | Grant | 1,265 | $0 | 5/7/2026 | View on chart |
| LAB | ▲ Buy | Grant | 94,592 | $0 | 6/20/2025 | View on chart |
| CERS | ▲ Buy | Grant | 60,000 | $0 | 6/3/2025 | View on chart |
| RVTY | ▲ Buy | Grant | 1,074 | $0 | 4/30/2025 | View on chart |
| RVTY | ▲ Buy | Grant | 1,338 | $0 | 4/30/2025 | View on chart |
| LAB | ▲ Buy | Grant | 43,128 | $0 | 6/28/2024 | View on chart |
| CERS | ▲ Buy | Grant | 40,000 | $200K | 6/5/2024 | View on chart |
| CERS | ▲ Buy | Open Market | 20,000 | $38K | 5/9/2024 | View on chart |
| RVTY | ▲ Buy | Grant | 977 | $0 | 5/1/2024 | View on chart |
| RVTY | ▲ Buy | Grant | 1,218 | $0 | 5/1/2024 | View on chart |
| LAB | ▲ Buy | Grant | 26,376 | $0 | 6/14/2023 | View on chart |
| CERS | ▲ Buy | Grant | 40,000 | $200K | 6/7/2023 | View on chart |
| RVTY | ▲ Buy | Grant | 783 | $0 | 5/15/2023 | View on chart |
| RVTY | ▲ Buy | Grant | 955 | $0 | 5/15/2023 | View on chart |
| LAB | ▲ Buy | Grant | 30,914 | $0 | 6/15/2022 | View on chart |
| CERS | ▲ Buy | Grant | 20,454 | $0 | 6/1/2022 | View on chart |
| RVTY | ▲ Buy | Grant | 610 | $0 | 5/6/2022 | View on chart |
| RVTY | ▲ Buy | Grant | 744 | $0 | 5/6/2022 | View on chart |
| LAB | ▲ Buy | Grant | 15,852 | $0 | 4/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Cerus to Present at 2026 AABB Annual Meeting
Cerus Corporation announced it will host a workshop and present abstracts at the upcoming 2026 AABB Annual Meeting. This event highlights the company's ongoing scientific engagement and clinical data sharing within the blood banking community. The announcement serves as a routine corporate update, providing context for the stock's current trading position near its support levels.
Cerus to Present at 2026 AABB Annual Meeting. Cerus Corporation announced it will host a workshop and present abstracts at the upcoming 2026 AABB Annual Meeting. This event highlights the company's ongoing scientific engagement and clinical data sharing within the blood banking community. The announcement serves as a routine corporate update, providing context for the stock's current trading position near its support levels.